v3.25.3
Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Disaggregation of Revenue [Line Items]        
Total revenues from anti-CD20 therapeutic programs $ 2,534.7 $ 2,465.8 $ 7,611.2 $ 7,221.2
Genentech        
Disaggregation of Revenue [Line Items]        
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA 101.0 94.8 292.4 285.3
Other revenues from anti-CD20 therapeutic programs 6.5 4.6 18.0 13.6
Revenue from anti-CD20 therapeutic programs        
Disaggregation of Revenue [Line Items]        
Total revenues from anti-CD20 therapeutic programs 493.9 446.2 1,339.4 1,284.7
Royalty Attributed To OCREVUS        
Disaggregation of Revenue [Line Items]        
Total revenues from anti-CD20 therapeutic programs $ 386.4 $ 346.8 $ 1,029.0 $ 985.8